A
884.30
9.33 (1.07%)
| Previous Close | 874.97 |
| Volume | 144,565 |
| Price / Earnings (Forward) | 26.75 |
| Price / Sales | 9.97 |
| Price / Book | 6.63 |
| 52 Weeks Range |
| Profit Margin | 40.26% |
| Operating Margin (TTM) | 17.50% |
| Diluted EPS (TTM) | 16.39 |
| Quarterly Revenue Growth (YOY) | 95.70% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | argenx SE | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.2 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | -5.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -1.11 |
Select this tab to load the latest available analysis.
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 55.54% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |